<DOC>
	<DOCNO>NCT02044848</DOCNO>
	<brief_summary>This study ass safety efficacy secukinumab preservation pancreatic beta cell patient newly-diagnosed type 1 diabetes mellitus .</brief_summary>
	<brief_title>Study Secukinumab Patients With Newly-diagnosed Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Males female age 1835 year initially ( subject age 817 may include later stage , start age 1217 year , follow age 811 year ) . Body weight 40120 kg initially ( subject weigh 2139 kg may include later stage ) . Recent onset type 1 diabetes mellitus , diagnose 100 day first dose . Peak stimulate Cpeptide level &gt; /= 0.2 pmol/L follow mixed meal tolerance test Any form diabetes autoimmune type 1 ( eg , type 2 diabetes , maturity onset diabetes young , latent autoimmune diabetes adult ) . Diabetic ketoacidosis within 2 week screen . Pregnancy lactation . Recent ( within 2 week screen ) , ongoing , chronic recurrent infectious disease . Active infection hepatitis B C , EpsteinBarr virus , cytomegalovirus , HIV . Tuberculosis infection . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>type 1 diabetes mellitus</keyword>
</DOC>